Renal Cell Cancer Clinical Trial
Official title:
An Open Label, Prospective, Observational, Local, Non-interventional Study of BeVacizumab (Avastin) and IntErpherone (IFN) Alpha 2a in Patients With Metastatic and Locally Advanced Renal Cell CAncer (VERA Study)
This prospective observational study will evaluate the efficacy and safety of Avastin (bevacizumab) in combination with interferon alpha 2a in patients with previously untreated metastatic renal cell cancer. Data will be collected from each patient for up to 4 years.
n/a
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00520403 -
A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.
|
Phase 2 | |
| Completed |
NCT00694096 -
Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor Response
|
Phase 1 | |
| Completed |
NCT00216801 -
Relationship of Ochratoxin A to Upper Urologic Cancers
|
N/A | |
| Completed |
NCT00172003 -
Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis
|
Phase 4 | |
| Completed |
NCT02493751 -
A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer (JAVELIN Renal 100)
|
Phase 1 | |
| Recruiting |
NCT01967407 -
IReversible Electroporation of Kidney Tumors Before Partial Nephrectomy.
|
Phase 1/Phase 2 | |
| Completed |
NCT00509704 -
Influence of Sutent on Tumor Vascularization and Necrosis in Patients With Renal Cell Carcinoma
|
N/A | |
| Terminated |
NCT05061537 -
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT04535921 -
Fear of Cancer Recurrence in Genitourinary Cancer
|
||
| Recruiting |
NCT04620603 -
Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT01829841 -
A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer
|
Phase 2 | |
| Completed |
NCT01122615 -
Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC)
|
Phase 1 | |
| Completed |
NCT00979329 -
Study on the Influence of Sunitinib and Sorafenib on Fatigue, QoL, Depression in Patients With Metastatic RCC or GIST
|
N/A | |
| Active, not recruiting |
NCT02429440 -
Adjuvant Antigen Specific Immunotherapy in Patients With Advanced Renal Cell Carcinoma Using Tumor Associated Peptides
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT02684006 -
A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)
|
Phase 3 | |
| Completed |
NCT02375776 -
Improving Outcomes in Cancer Patients on Oral Anti-Cancer Medications Using a Multi-modal Mobile Health Intervention
|
N/A | |
| Completed |
NCT01598597 -
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
|
N/A | |
| Completed |
NCT00465179 -
Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer
|
Phase 2 | |
| Completed |
NCT01158534 -
Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery
|
Phase 2 | |
| Terminated |
NCT00311467 -
Combined Treatment With Capecitabine and Immunotherapy Versus Immunotherapy Alone in Advanced Renal Cell Carcinoma
|
Phase 3 |